Interleukin-17 Inhibition in a Patient With Psoriasis and Concurrent Vitiligo

Katz, Kimberly; Rupley, Katherine; Sink, Jacquelyn R.; Shuley, Adele; Gottlieb, Alice B.

doi:10.1177/2475530318788943

Cited by 3 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent single-arm pilot study demonstrated that upon anti-IL-17A treatment, there was neither clinical nor laboratory improvement in active vitiligo patients (Speeckaert et al, 2019). In another study, IL-17 blockade using ixekizumab in a patient of psoriasis suffering from vitiligo, there was some improvement observed initially; however, there was no improvement in the vitiligo condition of the patient in long-term follow-up (Katz et al, 2018). Interestingly, in our study, there was no significant difference in skin-homing or systemic Th17 cells (CD4 + IL-17 + IL-4 − IFNγ -IL-9 − ) in active vitiligo as compared to the healthy controls (Figure 2d).…”

Section: Significancementioning

confidence: 99%

Presence and the roles of IL‐9/Th9 axis in vitiligo

Kumar

Marathe

Dhamija

et al. 2021

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

Vitiligo is an acquired idiopathic depigmentation disorder where selective damage of functional melanocytes causes hypo-pigmentation of the skin, hair, and mucosal surface (Ezzedine et al., 2015). The CD4 + and CD8 + T cells are described to be present at the junction of epidermis and dermis near the lesional skin of vitiligo, and the cytotoxic T cells are reported to kill melanocytes in vitiligo, emphasizing the roles of T cell-mediated immunity in vitiligo pathogenesis (van den Boorn et al., 2009). Recognizing imbalanced and dysfunctional effector T-cell subsets as well as dysregulated cytokine production might harbor significant potential for the targeted therapy. In addition, there are many indistinct facts about the loss of self-tolerance and dysregulated cytokine production in vitiligo pathogenesis.

show abstract

Section: Significancementioning

confidence: 99%

Presence and the roles of IL‐9/Th9 axis in vitiligo

Kumar

Marathe

Dhamija

et al. 2021

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

show abstract

“…Thus, the authors were of the opinion that targeting the IL17/Th17 axis may not be effective in treating vitiligo. 46 In another pilot trial, 8 patients with active vitiligo were treated with secukinumab 300 mg at weeks 0, 1, 2, 3, 4, and subsequently every 4 weeks for 7 months and followed up for an Other 5 patients attained stability which was maintained at 6 months post-treatment but did not attain the primary target of attaining >50% repigmentation. Th17 pathway was correlated with active disease.…”

Section: Il 17/23 Inhibitorsmentioning

confidence: 99%

“…The psoriatic lesions responded with complete clearance at 59 weeks, whereas the vitiligo lesions showed no response and in fact, the progression continued with the appearance of new depigmented patches in previously uninvolved areas. Thus, the authors were of the opinion that targeting the IL17/Th17 axis may not be effective in treating vitiligo 46 …”

Section: Etiopathogenesis Of Vitiligomentioning

confidence: 99%

Biologic and targeted therapeutics in vitiligo

Karagaiah

Schwaertz

Lotti

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Vitiligo is a long‐standing progressive autoimmune disease with depigmented macules/patches with significant psychological morbidity to the patients. From being one of the most poorly understood diseases in the past, there has been a rampant advance in determining the molecular and genetic factors influencing the disease process. More light has been shed on the complex intracellular environment and interplay between innate and adaptive immunity. Numerous cytokines and signaling pathways have been associated with disease pathogenesis in the recent past. Objective The aim of this review the efficacy of biologic and targeted therapeutics in vitiligo. Methods A detailed literature search was conducted on databases like PubMed, COCHRANE Central, EMBASE and Google Scholar using keywords—“biologics,” “vitiligo,” “treatment,” “repigmentation,” “JAK inhibitors,”, “TNF‐ꭤ inhibitors,” and “IL17/23 inhibitors,” Relevant studies and review articles in English were analyzed in detail and report was written. This article aimed at a comprehensive review of all the biologicals and newer targeted therapeutics tried in vitiligo and their efficacy with an insight into the potential complications arising as a result of the therapy. Results Most conventional vitiligo treatment modalities are restricted to generalized nonspecific immunosuppressants like topical and oral corticosteroids, calcineurin inhibitors, phototherapy, and surgical modalities. There have been reports and studies on the usage of biologicals in treating vitiligo. JAK inhibitors have shown good efficacy in vitiligo; however, it lacks substantial evidence in the form of randomized control trials. Similarly, the use of targeted therapeutics in treating vitiligo is substantiated by limited evidence and requires more randomized trials for further evidence. Conclusion JAK inhibitors have shown promising results and good tolerability; Adjuvant phototherapy can achieve a superior response compared to monotherapy. Though TNF‐ꭤ has been tried in a few cases, it is best used if vitiligo is present in association with other chronic autoimmune diseases for which it is indicated. More in vitro studies and clinical research are required to understand the pathogenesis clearly, and therapy has to be targeted at specific pathways for a better approach toward vitiligo. Treatment aimed at induction and differentiation of melanocytes may be added to achieve faster repigmentation.

show abstract

A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo

Russell,

Daniel

2024

Aust J Dermatology

View full text Add to dashboard Cite

Vitiligo is a chronic depigmenting disorder that significantly impacts the quality of life of patients. Though there have been significant advancements in targeted therapies in skin diseases such as psoriasis or eczema, the progress in the treatment of vitiligo has been slow, with minimal studies assessing the effect of biologics, though there has been recent evidence of the effectiveness of JAK inhibition. This paper reviews the published case reports and studies for the use of systemic targeted therapies including biologics and JAK inhibitors in vitiligo.

show abstract

Interleukin-17 Inhibition in a Patient With Psoriasis and Concurrent Vitiligo

Cited by 3 publications

References 36 publications

Presence and the roles of IL‐9/Th9 axis in vitiligo

Presence and the roles of IL‐9/Th9 axis in vitiligo

Biologic and targeted therapeutics in vitiligo

A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo

Contact Info

Product

Resources

About